We want to ensure optimum use of our website for you, and to continually improve our website. Therefore, we work with selected partners (e.g. Pardot). You can revoke your voluntary consent at any time. You can find further information and setting options under „Configure“ and in our data protection information.
Press Release Stockholm, Sweden, May 18, 2009 Elekta and Nucletron have reached an agreement to market and license Elekta's software system MOSAIQ®. Nucletron's existing Oncentra® Visir and Oncentra® Information Management customers will be offered a high-quality solution with excellent future prospects of continued innovation from the world's largest supplier of oncology software.
The business arrangement was reached in response to Nucletron’s recent decision to cease development, sales, and marketing of its Oncentra Visir and Oncentra Information Management product lines. Nucletron will focus efforts on innovations in brachytherapy and treatment planning for external beam.
MOSAIQ is an Oncology Information Management system that features an image-enabled electronic medical record fully integrated with comprehensive administrative management functionality that provides workflow automation designed specifically for the oncology specialty. Supporting multi-vendor, multi-disciplinary, and multi-site organizations, it unites diverse systems and ensures that all information about a cancer treatment is easily accessible throughout the entire treatment process.
“We look forward to working with Nucletron to deploy MOSAIQ throughout their installed base with minimal interruption to the cancer centers’ normal workflow routine. This will afford us a deeper understanding of the specific needs of an increasingly diverse oncology user base, which we will use to create more optimal informatics and workflow solutions for oncology professionals practicing in a variety of settings” says Jay Hoey, Executive Vice President of Elekta Software Systems.
“The decision to phase-out Oncentra Visir and Oncentra Information Management will enable us to further increase our efforts to innovate within the areas of brachytherapy and treatment planning for external beam. With this decision we enforce our mission and vision and refocus our strengths to live up to the promise of improving patient care,” says Jos Lamers, Chief Executive Officer of Nucletron B.V.